




Scientific Program

Saturday 25 November 2023

UAE TIME	TOPIC	SPEAKER
8:30 - 9:00	Registration	
9:00 - 9:05	Opening	Prof. Humaid Al Shamsi
 <h2>Early Stage NSCLC</h2> <p>Moderated by Dr. Hassan Jaafar & Dr. Mehdi Afrit</p>		
9:05 - 9:12	CheckMate 77T: Phase 3 study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIB NSCLC	Dr. Maroun El Khoury
9:12 - 9:19	Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)	Dr. Sonia Otsmane
9:19 - 9:26	Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase 3 CheckMate 816 trial	Dr. Saeed Rafii
9:26 - 9:33	IMpower010: exploratory analysis of disease-free survival (DFS) by TGFβ cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC)	Dr. Aref Chehal
9:33 - 9:40	Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase 3 AEGEAN trial	Dr. Salman Srayaldeen
9:40 - 9:47	Pathological Response to Neoadjuvant Tislelizumab (TIS) Plus Platinum-Doublet (PtDb) Chemotherapy (CT) in Resectable Stage II-III A NSCLC Patients (pts) in the Phase 3 (Ph3) RATIONALE-315 Trial	Dr. Urfan Ul Haq
9:47 - 9:54	ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC)	Dr. Amin Abyad
9:54 - 10:04	Panel Discussion	
 <h2>Advanced Stage NSCLC</h2> <p>Moderated by Dr. Hassan Ghazal & Dr. Hassan Jaafar</p>		
10:04 - 10:10	Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment in Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From MARIPOSA, a Phase 3, Global, Randomized, Controlled Trial	Dr. Emad Dawoud
10:10 - 10:16	Amivantamab Plus Chemotherapy (With or Without Lazertinib) vs Chemotherapy in EGFR-mutated Advanced NSCLC After Progression on Osimertinib: MARIPOSA-2, a Phase 3, Global, Randomized, Controlled Trial	Dr. Diaaeddine Trad
10:16 - 10:23	Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment in EGFR Exon 20 Insertion-mutated Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From PAPILLON, a Randomized Phase 3 Global Study	Dr. Nouri Benini

Scientific Program

Saturday 25 November 2023

UAE TIME	TOPIC	SPEAKER
10:23 - 10:33	Overall Survival from a Phase II Randomised Double-Blind Trial (PERLA) of Dostarlimab (dostar) + Chemotherapy (CT) vs Pembrolizumab (pembro) + CT in Metastatic Non-Squamous NSCLC	Prof. Solange Peters
10:33 - 10:40	Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): results of the randomized phase 3 study TROPION-Lung01	Dr. Cherian Thampy
10:40 - 10:50	Panel Discussion	
10:50 - 11:20	Satellite Symposium IO updates in the non-metastatic NSCLC management Speaker: Dr. Hassan Jaafar	 Bristol Myers Squibb™
11:20 - 11:50	Opening Ceremony	
11:50 - 12:10	Satellite Symposium Evolving Treatment Strategie in the Management of Metastatic EGFRm NSCLC	 AstraZeneca
Melanoma <small>Moderated by Dr. AbdelRahman Labban</small>		
12:10 - 12:18	Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801	Dr. Dima Abdul Jabbar
12:18 - 12:25	Atezolizumab, bevacizumab, and cobimetinib (TACo) in patients (pts) with PD1 refractory melanoma brain metastases (MBM)	Dr. Bilal Lababidi
12:325 - 12:35	Panel Discussion	
Sarcoma <small>Moderated by Dr. AbdelRahman Labban</small>		
12:35 - 12:42	A randomised, multicenter phase-III study comparing doxorubicin (dox) alone versus dox with trabectedin (trab) followed by trab in non-progressive patients (pts) as first-line therapy, in pts with metastatic or unresectable leiomyosarcoma (LMS): Final results of the LMS-04 study	Dr. AbdelRahman Labban
12:42 - 12:49	A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-ST5-0415)	Dr. Hala Abdel Latif
12:49 - 12:55	Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in patients (pts) with refractory metastatic sarcoma	Dr. Hassan Jaafar
12:55 - 13:00	Panel Discussion	
13:00 - 13:40	Lunch Break	
13:40 - 14:10	Satellite Symposium Transforming the management of upper GI cancers with Immuno Oncology Speaker: Dr. Nouri Bennini	 Bristol Myers Squibb™

Scientific Program

Saturday 25 November 2023

UAE TIME	TOPIC	SPEAKER
	Upper GI Moderated by Dr. Amin Abyad	
14:10 - 14:18	Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): a phase-III stepped-wedge cluster randomised trial	Dr. Rana Irfan Mahmood
14:18 - 14:26	Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): a multicenter randomized controlled trial	Dr. Rana Irfan Mahmood
14:26 - 14:34	Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The Phase 3 KEYNOTE-585 study"	Dr. Medhat Faris
14:34 - 14:42	Pembrolizumab plus Trastuzumab and Chemotherapy for HER2+ Metastatic Gastric or Gastroesophageal Junction (mG/GEJ) Adenocarcinoma: Survival results from the Phase 3, Randomized, Double-blind, Placebo-controlled KEYNOTE-811 Study	Dr. Medhat Faris
14:42 - 14:50	Updated efficacy and safety results from phase 3 GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma	Prof. Humaid Al Shamsi
14:50 - 14:58	Updated efficacy and safety results from phase 3 SPOTLIGHT study Last update: evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma	Prof. Humaid Al Shamsi
14:58 - 15:05	Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or SIROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): a multicenter, randomized, open-label, three-arm, phase 2/3 trial	Dr. Mohamed Omara
15:05 - 15:15	Panel Discussion	
15:15 - 15:35	Satellite Symposium Tislelizumab GI ESMO Updates Speaker: Prof. Shouki Bazarbashi	
15:35 - 15:45	Coffee Break	

Scientific Program

Saturday 25 November 2023

UAE TIME	TOPIC	SPEAKER
	LOWER GI Moderated by Prof. Humaid Al Shamsi & Dr. Falah Al Khatib	
15:45 - 15:55	Neoadjuvant Chemotherapy with CAPOX versus Chemoradiation for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial	Dr. Ibrahim Abu-Gheida
15:55 - 16:03	Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: a randomized phase III trial (UNION)	Dr. Ibrahim Abu-Gheida
16:03 - 16:11	Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase 3 KEYNOTE-177 study	Dr. Thanda Joshua
16:11 - 16:19	Circulating tumor (ct)DNA as a prognostic biomarker in patients (pts) with resected colorectal cancer (CRC): an updated 24 months (mos) disease free survival (DFS) analysis from GALAXY study (CIRCULATE-Japan)	Dr. Mudhasir Ahmad
16:19 - 16:27	The PEGASUS trial: post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients	Dr. Mudhasir Ahmad
16:27 - 16:37	FOXROT: results of embedded phase II evaluating the addition of panitumumab (pan) to neo-adjuvant FOLFOX for patients (pts) with KRAS-wt colon cancer (CC) with extended biomarker panel	Dr. Hassan Ghazal
16:37 - 16:45	First-line systemic treatment in patients with initially unresectable colorectal cancer liver metastases (CRLM): overall survival of the phase III CAIRO5 study of the Dutch Colorectal Cancer Group	Dr. Hassan Ghazal
16:45 - 16:55	Panel Discussion	
16:55 - 17:00	Closing Remarks	Prof. Humaid Al Shamsi



Scientific Program

Sunday 26 November 2023

UAE TIME	TOPIC	SPEAKER
8:30 - 9:00	Registration	
9:00 - 9:05	Opening	Prof. Humaid Al Shamsi
Gyne Session: Endometrial Cancer		
Moderated by Dr. Nadia Abdelwahed & Dr. Aydah Al Awadhi		
9:05 - 9:10	Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): Results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial	Dr. Dina Hamza
9:10 - 9:15	Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial	Dr. Dina Hamza
9:15 - 9:20	Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial	Dr. Nadia Abdelwahed
9:20 - 9:25	Panel Discussion	
Gyne Session: Ovarian Cancer		
Moderated by Dr. Saeed Rafii & Dr. Dina Hamza		
9:25 - 9:33	Efficacy and safety of senaparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer (FLAMES study): A randomized, double-blind, placebo-controlled, phase III trial	Dr. Kaltar Das
9:33 - 9:40	Panel Discussion	
Gyne Session: Cervical Cancer		
Moderated by Dr. Nadia Abdelwahed & Dr. Saeed Rafii		
9:40 - 9:45	Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study	Dr. Dalia El Shorbagy
9:45 - 9:50	Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: The GCIG INTERLACE trial III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study	Dr. Dalia El Shorbagy

Scientific Program

Sunday 26 November 2023

UAE TIME	TOPIC	SPEAKER
9:50 - 9:55	InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator's choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer	Dr. Mohammad Hourani
9:55 - 10:05	Panel Discussion	
10:05 - 10:30	Satellite Symposium Expanding Maintenance Options for Ovarian Cancer Patients Moderator: Dr. Emad Anwar Dawoud Speaker: Prof. Jonathan Ledermann	GSK
10:30 - 10:40	Coffee Break	
10:40 - 11:00	Satellite Symposium Trials to Clinical Practice: Patient Identification and Management of HR+ HER2- Early Breast Cancer Patients Speaker: Dr. Hassan Jaafar	Lilly
Early Breast Cancer Moderated by Dr. Faisal AlTerkait & Dr. Anwar Alnouri		
11:00 - 11:10	Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase 3 KEYNOTE-522 study	Dr. Nadia Abdelwahed
11:10 - 11:20	KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2- breast cancer	Dr. Husam Marashi
11:20 - 11:30	Invasive disease-free survival (iDFS) across key subgroups from the phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2- early breast cancer (EBC)	Dr. Aydah Al Awadhi
11:30 - 11:40	Panel Discussion	
11:40 - 12:00	Satellite Symposium HR+ HER2- mBC: How the latest data help inform treatment decision Moderator: Dr. Maroun El Khoury Speaker: Dr. Dima Abdul Jabbar	NOVARTIS
Metastatic Breast Cancer Moderated by Dr. Meteb Al-Foheidi & Dr. Aydah Al Awadhi		
12:00 - 12:07	Trastuzumab deruxtecan (T-DXd) versus treatment of physician choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomised, phase 3 DESTINY-Breast04 study	Prof. Guiseppe Curigliano
12:07 - 12:15	Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously treated inoperable or metastatic hormone receptor - positive, HER2-negative (HR+/HER2-) breast cancer (BC): primary results from the randomised Phase 3 TROPION-Breast01 trial	Prof. Guiseppe Curigliano

Scientific Program

Sunday 26 November 2023

UAE TIME	TOPIC	SPEAKER
12:15 - 12:22	Trastuzumab duocarmazine versus physician choice therapy in pre-treated HER2-positive metastatic breast cancer: final results of the phase III TULIP trial	Prof. Guiseppe Curigliano
12:22 - 12:30	Updated results from the phase 1/2 study of OP-1250, an oral complete oestrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer.	Dr. Sana Al Sukhun
12:30 - 12:37	Datopotamab deruxtecan (Dato-DXd) + durvulumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study	Dr. Sana Al Sukhun
12:37 - 12:45	SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC): results from a phase I/II, single-arm, basket trial	Dr. Sana Al Sukhun
12:45 - 12:52	Imlunestrant with or without everolimus or alpelisib, in ER+, HER2-advanced breast cancer (aBC): Results from the phase 1a/b EMBER study	Dr. Saeed Rafii
12:52 - 13:00	A multicenter, open-label, dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumors	Dr. Saeed Rafii
13:00 - 13:10	Panel Discussion	
13:10 - 13:30	Satellite Symposium Primary Endocrine Resistance in HR+ HER2- MBC: Defining Endocrine Resistance and the role of CDK4/6 Inhibition with Abemaciclib Speaker: Dr. Husam Marashi	
13:30 - 13:50	Satellite Symposium Treatment strategies after CDK4/6 inhibitors for patients with ER+/HER2 - aBC with focus on patients with ESR1m Moderator: Dr. Aref Chehal Speaker: Dr. Hassan Jaafar	 A Menarini Group Company
13:50 - 14:20	Lunch Break	
14:20 - 14:40	Satellite Symposium Expanding T-Dxd in Multiple Patients' Populations Moderator: Prof. Humaid Al Shamsi Speaker: Dr. Nadia Abdelwahed	

Scientific Program

Sunday 26 November 2023

UAE TIME	TOPIC	SPEAKER
GU Session: Baldder Cancer		
Moderated by Dr. Syed Hammad Tirmazy & Dr. Deborah Mukherji		
14:40 - 14:47	EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab (EV+P) Vs Chemotherapy (Chemo) in Previously Untreated Locally Advanced Metastatic Urothelial Carcinoma (la/mUC)	Dr. Deborah Mukherji
14:47 - 14:54	Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results from the phase 3 CheckMate 901 trial	Dr. Deborah Mukherji
14:54 - 15:00	Phase 3 THOR Study: Results of Erdafitinib (erda) vs Pembrolizumab (pembro) in Pretreated Patients (pts) With Advanced or Metastatic Urothelial Cancer (mUC) With Select Fibroblast Growth Factor Receptor Alterations (FGFRalt)	Dr. Syed Hammad Tirmazy
15:00 - 15:10	Panel Discussion	
15:10 - 15:30	Satellite Symposium The Current Standard of Care in the Management of Locally Advanced and Metastatic Urothelial Carcinoma Speaker: Dr. Deborah Mukherji	MERCK
15:30 - 15:40	Coffee Break	
15:40 - 16:00	Satellite Symposium Target PSMA +ve mCRPC Moderator: Dr. Diaeddine Trad Speaker: Dr. Dalia Elshorbagy	NOVARTIS
GU Session: Prostate Cancer		
Moderated by Dr. Syed Hammad Tirmazy & Dr. Deborah Mukherji		
16:00 - 16:07	Phase 3 trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)	Dr. Abdul Rahman El Kinge
16:07 - 16:15	Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration resistant prostate cancer (mCRPC): a randomised, phase 2 trial: ENZA-p (ANZUP 1901)	Dr Abdul Rahman El Kinge
16:15 - 16:22	Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Final Results of RADICALS RT Randomised Controlled Trial [NCT00541047]	Dr. Dorai Ramanathan
16:22 - 16:30	Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE	Dr. Dorai Ramanathan
16:30 - 16:40	Panel Discussion	

Scientific Program

Sunday 26 November 2023

UAE TIME	TOPIC	SPEAKER
	GU Session: Renal Cancer Moderated by Prof. Humaid Al Shamsi & Dr. Deborah Mukherji	
16:40 - 16:47	Phase 2 LITESPARK-003 Study of Belzutifan in Combination With Cabozantinib for Advanced Clear Cell Renal Cell Carcinoma (ccRCC)	Prof. Toni Choueiri
16:47 - 16:55	Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): randomized open-label phase 3 LITESPARK-005 study	Prof. Toni Choueiri
16:55 - 17:02	RENOTORCH: Toripalimab Combined with Axitinib versus Sunitinib in First-line Treatment of Advanced Renal-Cell Carcinoma (RCC): A randomized, Open-label, Phase 3 Study	Prof. Toni Choueiri
17:02 - 17:10	Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC). The TIDE-A study.	Prof. Toni Choueiri
17:10 - 17:20	Panel Discussion	
17:20 - 17:30	Closing Remarks & Appreciation Ceremony	Prof. Humaid Al Shamsi

